Welcome to our dedicated page for Enovis SEC filings (Ticker: ENOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enovis Corporation (NYSE: ENOV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Enovis describes itself as an innovation-driven medical technology growth company with two primary segments, Prevention & Recovery (P&R) and Reconstructive (Recon), and its filings offer detailed insight into how this orthopedic-focused business reports its financial condition, capital structure and governance matters.
Investors can review Form 8-K filings where Enovis reports material events, such as quarterly earnings releases, changes in senior leadership roles, amendments to its credit agreement and other significant corporate developments. For example, recent 8-Ks have covered second- and third-quarter financial results, a retirement transition for a senior human resources executive, and an amendment to the company’s credit agreement that adjusts maturity dates, leverage ratio thresholds and borrowing terms.
Beyond current reports, Enovis’ annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via EDGAR) typically contain segment information for Prevention & Recovery and Reconstructive, discussions of non-GAAP measures such as adjusted EBITDA and adjusted net income, and risk factor disclosures that may reference acquisitions and integration, including the acquisition of Lima. These filings help explain how the company evaluates its performance and manages its medical technology portfolio.
Stock Titan enhances access to Enovis filings by pairing real-time updates from EDGAR with AI-powered summaries that explain the key points in plain language. Users can quickly understand what a new 8-K, 10-Q or 10-K means for Enovis’ operations, capital structure or governance without reading every page. The platform also makes it easier to track items such as credit agreement amendments and other direct financial obligations that Enovis reports under the SEC’s requirements.
Enovis Corporation files its annual report describing a global medical technology business focused on reconstructive surgery and prevention & recovery devices. The company operates through two segments, sells broadly in the U.S. and Europe, and completed seven bolt‑on acquisitions in 2025 to expand products and distribution.
Enovis highlights extensive risks around acquisitions, leverage, regulation, reimbursement, data privacy and supply chains. It reports significant non‑cash Goodwill impairments of
Enovis Corporation reported fourth-quarter and full-year 2025 results showing steady growth but a large accounting loss driven by goodwill impairment. Fourth-quarter net sales were
For 2025, net sales reached
Enovis generated
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting a passive ownership stake in Enovis Corp common stock. As of 12/31/2025, Dimensional is deemed to beneficially own 2,781,936 shares, representing 4.9 % of Enovis’s common stock. It reports sole voting power over 2,724,038 shares and sole dispositive power over 2,781,936 shares, with no shared voting or dispositive power.
The shares are actually owned by various funds and accounts it advises (the “Funds”), and Dimensional disclaims beneficial ownership, stating that all securities are owned by the Funds. Dimensional also certifies that the holdings were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Enovis.
Enovis Corporation reported that Chief Administrative Officer Oliver Engert received an equity award in the form of restricted stock units on January 5, 2026. The award covers 42,640 shares of common stock at a stated price of $0.00 per share, reflecting a grant rather than an open‑market purchase.
According to the disclosure, these restricted stock units vest in three equal annual installments, beginning on the first anniversary of the grant date. Following this award, Engert is shown as beneficially owning 42,640 shares on a direct basis.
Enovis Corp filed an initial insider ownership report for Chief Administrative Officer Oliver Engert. As of the event date of 01/05/2026, the filing states that no Enovis securities are beneficially owned, with Table I showing 0 non-derivative securities held directly and Table II showing no derivative securities listed.
Enovis Corporation filed a current report to highlight that its management team is presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST (7:30 p.m. EST). The company states that a live webcast of the presentation and the related slide deck will be accessible through its website at www.enovis.com, with a replay available later the same day.
The slide presentation used at the conference is also furnished as Exhibit 99.1. Enovis notes that these presentation materials are being furnished to the SEC and are not deemed incorporated by reference into its Securities Act filings.
Enovis Corp director reports stock acquisition
A director of Enovis Corp (ENOV) reported acquiring 845 shares of the company’s common stock on 12/31/2025. The transaction was reported at a price of $0.00 per share, indicating this was a form of non-cash award such as a grant. Following this transaction, the reporting person beneficially owns 22,140 shares of Enovis common stock, held in direct ownership.
Enovis Corporation reported a planned leadership transition in its human resources function. Senior Vice President and Chief Human Resources Officer Patricia A. Lang informed the board she intends to retire from her current role on April 3, 2026, then serve in an advisory position until her full retirement from the company on April 3, 2027.
Enovis expects to appoint Laura Singleton, currently Vice President of Human Resources for the Reconstructive segment, as the new Senior Vice President and Chief Human Resources Officer effective April 3, 2026. Singleton joined Enovis in 2019 through its acquisition of DJO Global and has held multiple senior HR roles, and she holds a B.A. in history from Texas State University.
The company and Ms. Lang entered into a retirement transition agreement covering the period from April 3, 2026 through April 3, 2027. During this time, she will receive her current base salary for six months, after which it may be reduced by up to 50% for the remainder of the transition period, while remaining eligible for existing benefit plans and the annual incentive plan based on her actual base pay. The full agreement will be filed with Enovis’s Form 10-K for the year ended December 31, 2025.
Enovis Corp insider, a former Executive Vice President of Strategy & Business Development, reported multiple stock sales in a Form 4 filing. On December 9, 2025, the reporting person sold 666 shares of Enovis common stock at $27.21 per share in a direct transaction and held 160,449 shares directly afterward, plus 932 shares through a 401(k) plan. On the same date, three separate sales of 333 shares each were made at prices around $27.20 per share through trusts for the reporting person's daughter and son, leaving those trusts with no remaining shares.
Enovis Corporation entered into a Third Amendment to its existing credit agreement, updating the terms of its main debt facilities. The amended agreement provides a revolving credit facility of up to $1.1 billion and a $700.0 million term loan facility, and extends the maturity date for both to December 8, 2030, with an earlier maturity if, 91 days before that date, the company’s liquidity is less than 125% of the principal on its senior unsecured convertible notes.
The amendment keeps the required maximum Senior Secured Leverage Ratio at 3.50 to 1.00, but allows a temporary higher ratio after one or more acquisitions with aggregate consideration of $300.0 million or more, down from the prior $500.0 million threshold. It also increases the amount of unrestricted cash that can offset debt in leverage calculations to $400.0 million, from $150.0 million, reduces interest margins when the Total Leverage Ratio is below 1.50 to 1.00, and raises the cap on consideration for certain permitted acquisitions from $150.0 million to $200.0 million.
As of December 8, 2025, after applying the new terms, Enovis used part of the term loan proceeds to repay about $335.0 million of revolving borrowings, leaving $167.0 million outstanding under the revolving facility and $700.0 million outstanding under the term loan facility. Additional banks, including Truist Bank, DNB Capital LLC and Sumitomo Mitsui Banking Corporation, joined as lenders under the amended agreement.